Skip to main content

Drugs that replace statins but without the side effects approved for use by the NHS

  Statins often come with side affects such as aching muscles
Officials have approved the use of new cholesterol-reducing drugs that are as effective as statins but without the side effects.

Repatha and Praluent are in the vanguard of a new class of treatments that are expected to halve levels of ‘bad’ cholesterol in patients.

Scientists say they promise to save thousands of lives by preventing heart attacks and strokes in patients for whom statins do not work.

Some 325,000 patients could be taking the new drugs within weeks after the National Institute for Health and Clinical Excellence (NICE) approved them for use.

They will benefit those with inherited high cholesterol and those with heart disease who cannot cope with the side-effects of statins.

Statins, which are taken by more than seven million people daily in the UK, were developed 30 years ago but are renowned for side-effects such as muscle pain.

It is estimated that up to 20 percent of patients prescribed statins have to stop using the drugs because of muscle pain, leaving them at a high risk of heart attacks or strokes.

In some other patients statins do not work at all.

The new drugs will be self-administered with an injection pen and will be available for around 200,000 people who have symptoms of heart disease and who cannot tolerate statins or for whom statins do not work.

Credit: Telegraph
They will also be available for the roughly 125,000 patients who cannot bring their cholesterol down to a safe level with statins.

Professor Carole Longson, a director at NICE, said: “We are very pleased to be able to recommend alirocumab and evolocumab.

“People with hypercholesterolaemia or mixed dyslipidaemia who have a high risk of a heart attack or stroke despite taking the highest tolerated dose of other cholesterol-lowering drugs, have very few treatment options.

“The committee concluded that both drugs are effective in reducing levels of ‘bad cholesterol’ when compared with placebo, ezetimibe or statins in people with hypercholesterolaemia or mixed dyslipidaemia.

“However, both drugs are relatively expensive, costing over £4,000 per patients per year compared with about £350 for ezetemibe.

“Therefore the draft guidance recommends alirocumab [Praluent] and evolocumab [Rapetha] as a cost effective use of NHS resources only with the discounts agreed with the companies and only for people with hypercholesterolaemia or mixed dyslipidaemia whose cholesterol is still not under control despite making changes to their lifestyle and taking other cholesterol-lowering drugs.”

NHS providers are expected to begin receiving stocks of the new drugs over the next two months and every hospital will be given a further three months before they are obliged to offer the drugs to patients.

Drugs that replace statins but without the side effects approved for use by the NHS
by Henry Bodkin, telegraph.co.uk
http://flip.it/RBO.R

Popular posts from this blog

A historic moment in the Arab world

لحظة تاريخية في العالم العربي
As a democratic revolution led by tech-empowered young people sweeps the Arab world, Wadah Khanfar, Al Jazeera's director-general, shares a profoundly optimistic view of what's happening in Egypt, Tunisia, Libya and beyond. In the first talk posted online from the TED 2011 conference in California, Khanfar describes the powerful moment when people realised they could step out of their homes and ask for change. "كما ثورة ديمقراطية بقيادة الشباب التكنولوجيا ذات صلاحيات تجتاح العالم العربي ، وضاح خنفر ، الجزيرة المدير العام والأسهم وجهة نظر متفائلة بشكل كبير ما يحدث في مصر وتونس وليبيا وخارجها. وفي اول حديث له نشر على الانترنت من مؤتمر تيد 2011 في ولاية كاليفورنيا ، خنفر يصف لحظة قوية عند الناس أدركت أنها لا يمكن الخروج من منازلهم ونطلب من أجل التغيير."
http://www.ted.com/talks/wadah_khanfar_a_historic_moment_in_the_arab_world.html This talk was given on March 1, 2011 in Long Beach, California. TED 2011 is taking place between March 1 and Mar…

Our Captured, Wounded Hearts: Arundhati Roy On Balakot, Kashmir And India

With his reckless “pre-emptive” airstrike on Balakot in Pakistan, Prime Minister Narendra Modi has inadvertently undone what previous Indian governments almost miraculously, succeeded in doing for decades. Since 1947 the Indian Government has bristled at any suggestion that the conflict in Kashmir could be resolved by international arbitration, insisting that it is an “internal matter.” By goading Pakistan into a counter-strike, and so making India and Pakistan the only two nuclear powers in history to have bombed each other, Modi has internationalised the Kashmir dispute. He has demonstrated to the world that Kashmir is potentially the most dangerous place on earth, the flash-point for nuclear war. Every person, country, and organisation that worries about the prospect of nuclear war has the right to intervene and do everything in its power to prevent it.  Keep reading  >>>>


India has built around itself an aura of a global power whose time has come. For at least the last t…

Kashmir Jihad - Analysis & Options

PDF: http://bit.ly/2k0Vqpm

Kashmir is an incomplete agenda of partition of India. Since 1947, India and Pakistan have fought three wars on this issue. According to UN resolutions, Kashmiris have to decide their accession to Pakistan or India through impartial plebiscite, which could not take place due to Indian reluctance. Recently, India revoked Article 370 of the Constitution, which granted special autonomous status to Kashmir, it was done to unilaterally integrate occupied Kashmir. This is a violation of the UN resolutions and the Simla bilateral agreement, which demands to maintain status quo until the final settlement. The US and world powers are emphasizing that Kashmir should be resolved bilaterally, though India has refused to hold talks with Pakistan. In the present scenario, while India has turned Kashmir into the largest prison of 9 million people, denying basic human rights and oppressing the Kashmiris' who want freedom from India, Pakistan cannot watch as a silent spec…